Jaguar health announces appointment of martire particco, md, as chief medical officer of napo therapeutics

Napo therapeutics is focused on expanding crofelemer access in europe for treatment of patients suffering from rare diseases - beginning with short bowel syndrome (sbs) for sbs, napo therapeutics has been granted orphan-drug designation for crofelemer by the european medicines agency, and jaguar health has been granted orphan-drug designation for crofelemer by the fda san francisco, ca and milan, italy / accesswire / january 24, 2022 / jaguar health (nasdaq:jagx) and napo therapeutics s.p.a., an italian corporation established by jaguar health in italy, today announced the appointment of martire particco, md, a physician with 30+ years of experience in europe's pharmaceutical industry and in clinical practice, as chief medical officer of napo therapeutics.
JAGX Ratings Summary
JAGX Quant Ranking